GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » EPS without NRI

Endonovo Therapeutics (Endonovo Therapeutics) EPS without NRI : $-0.00 (TTM As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics EPS without NRI?

Endonovo Therapeutics's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Endonovo Therapeutics's EPS without NRI or its related term are showing as below:

During the past 13 years, Endonovo Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 87.50% per year. The lowest was -162.00% per year. And the median was 3.40% per year.

ENDV's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.1
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Endonovo Therapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01.

Endonovo Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.04.


Endonovo Therapeutics EPS without NRI Historical Data

The historical data trend for Endonovo Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics EPS without NRI Chart

Endonovo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.20 -0.44 -0.05 -0.03 -

Endonovo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.01 0.01 - -

Competitive Comparison of Endonovo Therapeutics's EPS without NRI

For the Biotechnology subindustry, Endonovo Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endonovo Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's PE Ratio without NRI falls into.



Endonovo Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Endonovo Therapeutics  (OTCPK:ENDV) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Endonovo Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Endonovo Therapeutics (Endonovo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
Executives
Alan Brian Collier director, 10 percent owner, officer: CEO 6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann 10 percent owner, officer: President 6320 CANOGA AVENUE, WOODLAND HILLS CA 91367

Endonovo Therapeutics (Endonovo Therapeutics) Headlines

From GuruFocus

Endonovo Targets Dept. of Defense, VA & Federal Contracts

By Stock market mentor Stock market mentor 01-03-2023

Endonovo Names Ira Weisberg President to Guide Global Medical Expansion

By Value_Insider Value_Insider 11-30-2022

Endonovo Partners with International Distributor for SofPulse� Line

By Stock market mentor Stock market mentor 01-26-2023

Endonovo Launches SofPulse� into the Veterans Administration

By sperokesalga sperokesalga 05-02-2023

New Details on Endonovo's Spin-Off of SofPulse, Inc.

By Stock market mentor Stock market mentor 01-19-2023

Endonovo Announces Plans for Spin-off of Medical IP and Assets

By Value_Insider Value_Insider 12-15-2022

Endonovo Launches Telehealth Initiative

By Value_Insider Value_Insider 12-13-2022

Endonovo Therapeutics Issues Corporate Update

By Value_Insider Value_Insider 11-07-2022